Recent News

• 03.24.2026 - Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
• 03.16.2026 - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
• 03.12.2026 - Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
• 03.09.2026 - Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
• 03.09.2026 - Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
• 02.26.2026 - Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.17.2026 - 144 Report of proposed sale of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.13.2026 - 144 Report of proposed sale of securities
• 03.12.2026 - 144 Report of proposed sale of securities
• 03.12.2026 - 8-K Current report
• 03.12.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.12.2026 - EX-99.1 EX-99.1
• 03.10.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 144 Report of proposed sale of securities